1. Product
Overview
1.1. Market
Definition
1.2. Scope
of the Market
1.2.1. Markets
Covered
1.2.2. Years
Considered for Study
1.2.3. Key
Market Segmentations
2. Research
Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key
Industry Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validation
2.7. Assumptions
and Limitations
3. Executive
Summary
3.1. Overview
of the Market
3.2. Overview
of Key Market Segmentations
3.3. Overview
of Key Market Players
3.4. Overview
of Key Regions/Countries
3.5. Overview
of Market Drivers, Challenges, Trends
4. Voice
of Customer
5. Global
Acquired Orphan Blood Diseases Therapeutics Market Outlook
5.1. Market
Size & Forecast
5.1.1. By
Value
5.2. Market
Share & Forecast
5.2.1. By
Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated
Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others)
5.2.2. By
Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von
Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic
Syndrome, Others)
5.2.3. By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
5.2.4. By
Company (2024)
5.3. Market
Map
6. Asia
Pacific Acquired Orphan Blood Diseases Therapeutics Market Outlook
6.1. Market
Size & Forecast
6.1.1. By
Value
6.2. Market
Share & Forecast
6.2.1. By Therapy
6.2.2. By
Disease Indication
6.2.3. By Distribution
Channel
6.2.4. By
Country
6.3. Asia
Pacific: Country Analysis
6.3.1. China
Acquired Orphan Blood Diseases Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By
Therapy
6.3.1.2.2. By
Disease Indication
6.3.1.2.3. By
Distribution Channel
6.3.2. India
Acquired Orphan Blood Diseases Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By
Therapy
6.3.2.2.2. By
Disease Indication
6.3.2.2.3. By
Distribution Channel
6.3.3. Australia
Acquired Orphan Blood Diseases Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By
Therapy
6.3.3.2.2. By
Disease Indication
6.3.3.2.3. By
Distribution Channel
6.3.4. Japan
Acquired Orphan Blood Diseases Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By
Therapy
6.3.4.2.2. By
Disease Indication
6.3.4.2.3. By
Distribution Channel
6.3.5. South
Korea Acquired Orphan Blood Diseases Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By
Therapy
6.3.5.2.2. By
Disease Indication
6.3.5.2.3. By
Distribution Channel
7. Europe
Acquired Orphan Blood Diseases Therapeutics Market Outlook
7.1. Market
Size & Forecast
7.1.1. By
Value
7.2. Market
Share & Forecast
7.2.1. By
Therapy
7.2.2. By
Disease Indication
7.2.3. By
Distribution Channel
7.2.4. By
Country
7.3. Europe:
Country Analysis
7.3.1. France
Acquired Orphan Blood Diseases Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By
Therapy
7.3.1.2.2. By
Disease Indication
7.3.1.2.3. By
Distribution Channel
7.3.2. Germany
Acquired Orphan Blood Diseases Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By
Therapy
7.3.2.2.2. By
Disease Indication
7.3.2.2.3. By
Distribution Channel
7.3.3. Spain
Acquired Orphan Blood Diseases Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By
Therapy
7.3.3.2.2. By
Disease Indication
7.3.3.2.3. By
Distribution Channel
7.3.4. Italy
Acquired Orphan Blood Diseases Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By
Therapy
7.3.4.2.2. By
Disease Indication
7.3.4.2.3. By
Distribution Channel
7.3.5. United
Kingdom Acquired Orphan Blood Diseases Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By
Therapy
7.3.5.2.2. By
Disease Indication
7.3.5.2.3. By
Distribution Channel
8. North
America Acquired Orphan Blood Diseases Therapeutics Market Outlook
8.1. Market
Size & Forecast
8.1.1. By
Value
8.2. Market
Share & Forecast
8.2.1. By
Therapy
8.2.2. By
Disease Indication
8.2.3. By
Distribution Channel
8.2.4. By
Country
8.3. North
America: Country Analysis
8.3.1. United
States Acquired Orphan Blood Diseases Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By
Therapy
8.3.1.2.2. By
Disease Indication
8.3.1.2.3. By
Distribution Channel
8.3.2. Mexico
Acquired Orphan Blood Diseases Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By
Therapy
8.3.2.2.2. By
Disease Indication
8.3.2.2.3. By
Distribution Channel
8.3.3. Canada
Acquired Orphan Blood Diseases Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By
Therapy
8.3.3.2.2. By
Disease Indication
8.3.3.2.3. By
Distribution Channel
9. South
America Acquired Orphan Blood Diseases Therapeutics Market Outlook
9.1. Market
Size & Forecast
9.1.1. By
Value
9.2. Market
Share & Forecast
9.2.1. By
Therapy
9.2.2. By
Disease Indication
9.2.3. By
Distribution Channel
9.2.4. By
Country
9.3. South
America: Country Analysis
9.3.1. Brazil
Acquired Orphan Blood Diseases Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By
Therapy
9.3.1.2.2. By
Disease Indication
9.3.1.2.3. By
Distribution Channel
9.3.2. Argentina
Acquired Orphan Blood Diseases Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By
Therapy
9.3.2.2.2. By
Disease Indication
9.3.2.2.3. By
Distribution Channel
9.3.3. Colombia
Acquired Orphan Blood Diseases Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By
Therapy
9.3.3.2.2. By
Disease Indication
9.3.3.2.3. By
Distribution Channel
10. Middle
East and Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook
10.1. Market
Size & Forecast
10.1.1. By
Value
10.2. Market
Share & Forecast
10.2.1. By
Therapy
10.2.2. By
Disease Indication
10.2.3. By
Distribution Channel
10.2.4. By
Country
10.3. MEA:
Country Analysis
10.3.1. South
Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By
Therapy
10.3.1.2.2. By
Disease Indication
10.3.1.2.3. By
Distribution Channel
10.3.2. Saudi
Arabia Acquired Orphan Blood Diseases Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By
Therapy
10.3.2.2.2. By
Disease Indication
10.3.2.2.3. By
Distribution Channel
10.3.3. UAE
Acquired Orphan Blood Diseases Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By
Therapy
10.3.3.2.2. By
Disease Indication
10.3.3.2.3. By
Distribution Channel
11. Market
Dynamics
11.1. Drivers
11.2. Challenges
12. Market
Trends & Developments
12.1. Recent
Developments
12.2. Product
Launches
12.3. Mergers
& Acquisitions
13. Global
Acquired Orphan Blood Diseases Therapeutics Market: SWOT Analysis
14. Porter’s
Five Forces Analysis
14.1. Competition
in the Industry
14.2. Potential
of New Entrants
14.3. Power
of Suppliers
14.4. Power
of Customers
14.5. Threat
of Substitute Product
15. PESTLE
Analysis
16. Competitive
Landscape
16.1. Alexion
Pharmaceuticals, Inc.
16.1.1. Business
Overview
16.1.2. Company
Snapshot
16.1.3. Products
& Services
16.1.4. Financials
(In case of listed companies)
16.1.5. Recent
Developments
16.1.6. SWOT
Analysis
16.2. Amgen,
Inc.
16.2.1. Business
Overview
16.2.2. Company
Snapshot
16.2.3. Products
& Services
16.2.4. Financials
(In case of listed companies)
16.2.5. Recent
Developments
16.2.6. SWOT
Analysis
16.3. Celgene
Corporation
16.3.1. Business
Overview
16.3.2. Company
Snapshot
16.3.3. Products
& Services
16.3.4. Financials
(In case of listed companies)
16.3.5. Recent
Developments
16.3.6. SWOT
Analysis
16.4. Eli
Lilly and Company
16.4.1. Business
Overview
16.4.2. Company
Snapshot
16.4.3. Products
& Services
16.4.4. Financials
(In case of listed companies)
16.4.5. Recent
Developments
16.4.6. SWOT
Analysis
16.5. Sanofi
SA
16.5.1. Business
Overview
16.5.2. Company
Snapshot
16.5.3. Products
& Services
16.5.4. Financials
(In case of listed companies)
16.5.5. Recent
Developments
16.5.6. SWOT
Analysis
16.6. GlaxoSmithKline
plc
16.6.1. Business
Overview
16.6.2. Company
Snapshot
16.6.3. Products
& Services
16.6.4. Financials
(In case of listed companies)
16.6.5. Recent
Developments
16.6.6. SWOT
Analysis
16.7. Cyclacel
Pharmaceuticals Inc.
16.7.1. Business
Overview
16.7.2. Company
Snapshot
16.7.3. Products
& Services
16.7.4. Financials
(In case of listed companies)
16.7.5. Recent
Developments
16.7.6. SWOT
Analysis
16.8. Onconova
Therapeutics, Inc
16.8.1. Business
Overview
16.8.2. Company
Snapshot
16.8.3. Products
& Services
16.8.4. Financials
(In case of listed companies)
16.8.5. Recent
Developments
16.8.6. SWOT
Analysis
16.9. Incyte
Corporation
16.9.1. Business
Overview
16.9.2. Company
Snapshot
16.9.3. Products
& Services
16.9.4. Financials
(In case of listed companies)
16.9.5. Recent
Developments
16.9.6. SWOT
Analysis
16.10.CTI
BioPharma Corp
16.10.1. Business
Overview
16.10.2. Company
Snapshot
16.10.3. Products
& Services
16.10.4. Financials
(In case of listed companies)
16.10.5. Recent
Developments
16.10.6. SWOT
Analysis
17. Strategic
Recommendations
18. About Us &
Disclaimer